Arcade Therapeutics is very proud to announce that our latest clinical trial results were published in the Journal of Anxiety Disorders, a peer-reviewed journal dedicated to advancing the understanding, assessment, treatment, and prevention of anxiety disorders.  In our quest to be a science-first digital medicine company, this type of publication is critically important to show howour products deliver real clinical impact to patients, and can be trusted by healthcare providers. This study focused on Social Anxiety Disorder as an endpoint, a large and increasingly recognized area of anxiety that has grown in significance after the pandemic. The study which was part of our latest FDA Pre-Submission showed that patients in the active group saw significant reductions in symptoms. Overall 90% saw an average of 33% symptom reduction within a 30 day period, and 68% dropped a full severity level using our game-based training method.

Hats off to our Co-Founder and Chief Science Officer Dr. Tracy Dennis-Tiwary on her work here along with the other team members who led this work for us. We are already seeing great traction as more of our partners and clients recognize the credibility of our solutions as a new options for mental health treatments.

We have already seen positive industry recognition which you can see in our CEO's LinkedIn post (who you can also follow) here!